BCX4161

DRUG4 trials

Sponsors

BioCryst Pharmaceuticals

Conditions

HAEHereditary Angioedema

Phase 1

A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161

CompletedNCT02125162

BioCryst PharmaceuticalsHereditary Angioedema

Start: 2014-04-30End: 2014-07-31Updated: 2014-08-15

Study to Determine How BCX4161 is Metabolized and Eliminated by the Body

CompletedNCT02218294

BioCryst PharmaceuticalsHereditary Angioedema

Start: 2014-08-31End: 2014-09-30Updated: 2014-10-29

Phase 2

Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE

CompletedNCT01984788

BioCryst PharmaceuticalsHereditary Angioedema

Start: 2013-11-30End: 2014-05-31Updated: 2014-08-18

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks

CompletedNCT02303626

BioCryst PharmaceuticalsHAE, Hereditary Angioedema

Start: 2014-12-17End: 2016-01-31Updated: 2025-11-17

Related Papers

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.

2019-02-0116 citations